Genes that cause severe liver disease in children also influence risk and severity of common liver conditions in adults

Mushi JM[1]*, Sharma PJ[1]*, Schofield A[1,2], Chen VL[3], Cordell HJ[4], Davies SP[2], Gupte GL[5], Hirschfield GM[6], Jeyaraj R[2], Jones DE[7], Mells GF[8], Oo YH[2], Sandford RN[9], Siminovitch KA[10,11], Xu J[12†], Zhu K[12], Trauner M[13], Mann JP[2,5#].

*Joint first authors
[#]Correspondence

Affiliations
[1] Medical school, College of medicine and health, University of Birmingham, UK.
[2] Department of Immunology & Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, UK.
[3] Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
[4] Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK
[5] Liver Unit (including small bowel transplantation), Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK
[6] The Autoimmune and Rare Liver Disease Programme, Division of Gastroenterology and Hepatology, Toronto General Hospital, Toronto, ON, Canada
[7] NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle, UK
[8] Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
[9] Academic Department of Medical Genetics, University of Cambridge, Cambridge, United Kingdom.
[10] Departments of Medicine, Immunology and Medical Sciences, University of Toronto, Toronto, Ontario, Canada
[11] Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute and Toronto General Research Institute, Toronto, Ontario, Canada
[12] Gilead Sciences Inc., Foster City, California, USA
[13] Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
[†]Affiliation at the time research was conducted.

Correspondence:
Dr. Jake P. Mann
j.p.mann@bham.ac.uk
Centre for Liver and gastroenterology research, Department of Immunology & Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, UK
+44 (0)121 414 3344

Funding

AS, SPD, YHO, and JPM: NIHR BRC Birmingham.
JPM is supported by grants from Birmingham Health Partners, NIHR ACL (CL-2022-09-005), Royal Society (RG\R1\241312), BSPGHAN-Guts (BSPGHAN2023_01), ESPGHAN, Royal College Physicians Dame Sheila Sherlock Bursary, and Little Princess Trust (CCLGA 2024 10 Mann).

Conflicts of interest
KZ is an employee of Gilead Sciences Inc. JX was an employee of Gilead Sciences Inc. at the time the research was conducted.

Acknowledgements
We thank Gabriel Cuella Partida for his advice on statistical genetics. We also thank the Birmingham NIHR Biomedical Research Centre, Centre for Liver and Gastrointestinal Research, and University of Birmingham Imaging Facility for their support.

Contributions
CRediT: Mushi J: Data curation, Formal Analysis, Visualization, Writing – original draft, Writing – review & editing; Sharma PJ: Data curation, Formal Analysis, Visualization, Writing – original draft, Writing – review & editing; Schofield A: Data curation, Formal Analysis; Chen VL: Data curation, Formal Analysis, Writing – review & editing; Cordell HJ: Data curation, Formal Analysis, Writing – review & editing; Davies SP: Data curation, Formal Analysis, Writing – review & editing; Gupte GL: Data curation, Formal Analysis, Writing – review & editing; Hirschfield GM: Data curation, Formal Analysis, Writing – review & editing; Jeyaraj R: Data curation, Formal Analysis, Writing – review & editing; Jones DE: Data curation, Formal Analysis, Writing – review & editing; Mells GF: Data curation, Formal Analysis, Writing – review & editing; Oo YH: Data curation, Formal Analysis, Writing – review & editing; Sandford RN: Data curation, Formal Analysis, Writing – review & editing; Siminovitch KA: Data curation, Formal Analysis, Writing – review & editing; Xu J: Data curation, Formal Analysis, Funding acquisition, Investigation, Writing – review & editing; Zhu K: Data curation, Formal Analysis, Funding acquisition, Investigation, Writing – review & editing; Trauner M: Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Writing – review & editing; Mann JP: Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Visualization, Writing – original draft, Writing – review & editing

Pre-print
This manuscript is available as a pre-print at:
https://doi.org/10.1101/2025.05.09.25326407

Abstract

Background and aims
Rare, pathogenic variants can cause severe liver disease, requiring transplantation in childhood, but it is unclear how common variants in the same genes affect adults. Here, we aimed to establish population-level genetic evidence for whether 'monogenic' diseases are associated with liver injury in adulthood.

Methods
We identified 99 genes where pathological mutations cause significant liver disease in children. For each, we used data from over 1.8 million adults to identify associations with biomarkers of liver injury. Observations were validated in multiple cohorts of adults with clinical liver disease and transcriptomics. Finally, we illustrated the importance of the JAG1-NOTCH pathway on the ductular reaction using immunohistochemistry.

Results
Most genes (56% (55/99)) had at least 'moderate' evidence of association with liver-related traits at a population level. We identified 82 genome-wide ($p<5x10^{-8}$) associations with markers of liver injury in 41% (41/99) of genes. Loss of function variants in these genes had a ten-fold greater effect on liver enzymes and well-established variants in *PNPLA3* had a three-fold greater effect. Variants in *ABCC2*, *ASL*, *BCS1L*, *HFE*, and *SERPINA1* were linked with presence of clinical liver disease in adults. Aggregated effects of 35 variants as polygenic risk score (PRS) was associated with 0.6% lower prevalence of MASLD between highest and lowest PRS groups. Transcriptional expression of 30% of genes was associated with severity of MASLD. Expression of JAG1-NOTCH2 pathway was associated with severity of PSC. JAG1 and NOTCH2 were expressed in injured bile ducts but not adjacent unaffected ducts.

Conclusions
Onset and severity of liver disease in adulthood is influenced by genes that also cause severe monogenic liver disease in children.

Keywords
Genome wide association study; cirrhosis; next generation sequencing; paediatrics

Introduction

Germline variants with major functional impact cause rare, apparently monogenic diseases across all body systems. Such disorders (e.g. Alagille syndrome, Wilson disease, progressive familial intrahepatic cholestasis (PFIC)) are frequent indications for liver transplantation in children[1]. However, many conditions (e.g. Alagille syndrome) have wide clinical variation [2] and higher predicted genetic prevalence than observed clinical prevalence[3]. This may be due to incomplete penetrance, variable expressivity, and/or influences of environmental factors. Other disorders (e.g. progressive familial intrahepatic cholestasis) show close genotype-phenotype correlation, with more severe protein-truncating mutations requiring earlier transplantation[4].

Large, population-scale sequencing studies have led to the identification of milder phenotypes of monogenic disorders across a range of conditions[5]. Such studies have demonstrated that variants in HFE (e.g. C282Y) and SERPINA1 confer additional risk towards chronic liver disease, consistent with an autosomal dominant method of inheritance[6,7]. However, it is not clear whether this principle extends to genes that cause ultra-rare monogenic liver diseases. Particularly as many disorders (e.g. *DCDC2*-associated neonatal sclerosing cholangitis) manifest a severe phenotype with biallelic mutations[8] and are classically believed not to have a phenotype in the haploinsufficient state, though recent data has started to challenge this[9].

Genetic testing for liver disease typically involves large, multigene panels. These often identify coding variants of uncertain significance for infants with neonatal cholestasis. Little is known about whether such variants confer risk later in life or have clinical relevance for the general population. In this study, we find evidence that 'monogenic' liver disorders show mild phenotypes in adulthood.

Materials and methods

Identification of genes for inclusion

First, we identified a list of genes that are robustly associated with monogenic liver disease. Criteria for inclusion were: (1) the condition causes at least one of: moderate hepatic fibrosis, acute and/or recurrent liver failure, or primary liver cancer; (2) at least two separate case series of patients have been reported; (3) variants in a single gene are regarded as causal according to ACMG criteria[10] review on Online Mendelian Inheritance in Man (OMIM)[11]. Genes were excluded if they were part of a generalised hereditary cancer syndrome (e.g. *TP53*), or if they were an indication for liver transplantation due to systemic effects without any evidence of clinically significant liver disease (e.g. *PKU*).

To identify genes, first, we searched PubMed and Google Scholar for: ("genetic" or "hereditary" or "monogenic") AND ("liver" or "biliary" or "fibrosis" or "hepatoblastoma" or "hepatocellular"). Relevant articles were reviewed to identify genes for inclusion. Next, we searched databases of genetic disorders (National Organisation for Rare Diseases (https://rarediseases.org/) and OMIM[11]) for the above liver-related terms. Lastly, we reviewed the Genomics England targeted sequencing panels (https://panelapp.genomicsengland.co.uk/) for Ductal plate malformation, Mitochondrial liver disease, including transient infantile liver failure, Neonatal cholestasis, and Polycystic liver disease.

Gene-level association testing

Next, we determined the evidence for association between each of these 99 genes and liver-related traits using the HuGE calculator[12] and GeneBass[13] gene burden testing. The liver-related traits were: alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total and conjugated bilirubin, cirrhosis, cholecystitis, and cholangitis. For each gene, we obtained HuGE scores for liver-related traits from the Common Metabolic Diseases Knowledge Portal (CMDKP, cmdkp.org, accessed February 2025). HuGE scores are calculated using the effect of both thousands of common and rare variants in (or near) each gene from multiple GWAS with sample sizes up to 1 million individuals, as described elsewhere in detail[12]. Evidence is graded from 'anecdotal' to 'compelling', after adjustment for multiple testing.

GeneBass is a curated database of results from UK BioBank whole exome sequencing and methods used for burden testing are described in detail elsewhere[13]. In short, the effects of multiple variants within a single gene are added together, based upon their predicted impact on protein function. Variants are classified into those predicted to cause loss of function (pLoF), missense mutations, and those without effect on amino acid sequence (synonymous). We extracted pLoF, missense, and synonymous gene burden testing (using SKAT-O p-values) and adjusted for multiple testing using Benjamini-Hochberg method.

Variant-trait associations

We then identified variants in (or near (±50kb)) each of the 99 candidate genes that were associated with liver-related traits at genome-wide significance ($p<5x10^{-8}$). To do this, we obtained variant-trait associations from CMDKP, GeneBass, and OpenTargets Genetics[14]. UCSC LiftOver Tool[15] was used to convert from GRCh37 to GRCh38. We filtered for liver-

related traits and genome-wide significant variants. Where duplicates were identified (from different data sources), the association with the smallest p-value was kept. To adjust for multiple testing, we only kept variants with $p<5x10^{-8}$.

Variant annotation

We annotated variants with functional predictions using Ensembl's variant effect predictor[16]. LocusZoom was used to illustrate locus-trait associations[17]. Variants were further annotated with expression-trait quantitative loci (eQTL) in liver tissue using data from Genotype-Tissue Expression (GTEx) Project via the EBI eQTL catalogue[18].

To determine whether causal variants were shared across traits (e.g. ALT and GGT), we performed colocalization analysis using summary statistics from the largest available GWAS of liver enzymes[19] (as full bottom-line association results were not available from CMDKP). Summary statistics were standardised using MungeSumstats[20] and converted into variant call format using gwas2vcf[21] for analysis using gwasglue. Evidence of colocalization due to a single causal variant was defined by $PP.H_4 \geq 0.8$[22].

We manually reviewed evidence from Open Targets Genetics[14] and FORGEdb[23] for every variant to determine whether the look-up gene was likely to be causal. For variants to be included as likely linked to the look-up gene required, at least one of: coding or intronic within the gene of interest, significant eQTL, or in strong LD ($R^2>0.8$) with another variant that fulfilled the above criteria.

To determine the number of unique variants, we subsequently performed clumping using 1000 genomes phase 3[24] reference data with PLINK2[25] --clump-p1 1e-5 --clump-r2 0.05 --clump-kb 250. LeadSNPs were then taken forwards for subsequent validation.

Clinical liver cohort validation

Next, we replicated associations in separate genome-wide association studies of patients with clinically significant common liver diseases. We obtained summary statistics from six studies: primary sclerosing cholangitis (PSC)[26], primary biliary cholangitis (PBC)[27], metabolic-dysfunction associated steatotic liver disease (MASLD)[28], and all-cause cirrhosis[6,29,30]. None of these studies were included in the discovery searches. Replication required false-discovery rate (FDR (Benjamini-Hochberg)) adjusted p-FDR < 0.05 in at least one cohort with clinical liver disease.

All of Us validation and polygenic risk score

All of Us is a population-level dataset of approximately 350,000 individuals from the United States of America. Inclusion criteria and genotyping of the All of Us cohort are described in detail elsewhere[31]. All of Us data was accessed using Research Project ID 69402. Genetic analyses were restricted to the independent GWAS-significant variants identified above. 35 out of 82 variants were present in the dataset. Individuals were included in the current analysis if there was available data on age, sex, liver enzymes, BMI, and presence or absence of chronic liver disease. ICD diagnostic codes were used to identify cases of chronic liver disease; full

details of diagnostic codes used are available in code. Diagnoses of MASLD were established using codes K75.8, K76.0, and K70.1. Genomic analyses were conducted using Hail[32]. Individual variant-trait analyses were adjusted for age, sex, and the first 9 principal components (PC) of genetic ancestry. Bonferroni-adjusted p-value of .05/35= .0014 was used for significance.
We then constructed an unweighted polygenic risk score (PRS) through aggregation of number of alternate alleles (as identified in the original variant discovery above) for each individual. The presence or absence of clinical liver disease was tested against PRS using multivariable logistic regression adjusted for age, sex, and body mass index (BMI).

Gene expression in MASLD

We then assessed whether expression of the candidate genes contribute to severity adult liver disease. Transcriptional expression of 99 genes was assessed in GSE135251[33], which contains RNA sequencing data from 216 individuals across the spectrum of MASLD (control to F4). Raw counts were filtered for low expressed genes then differential gene expression was performed between patients with MASLD and no fibrosis (MASL F0) and steatohepatitis with cirrhosis (MASH F4) with Benjamini–Hochberg adjusted p-values <0.05 as significant. 94 out of 99 genes were available for analysis in the dataset. Violin plots demonstrate normalised counts. In addition, we performed one-way ANOVAs to look for any variation between groups in candidate genes, with Bonferroni-adjusted p-values (p.adj) <0.05 as significant.

JAG1 transcript expression in PSC and MASLD

Given the strong signal for JAG1 in the above analyses we aimed to validate the transcriptional results in additional cohorts of PSC and MASLD. Patients with PSC who were recruited to the phase 2b trial of simtuzumab (NCT01672853)[34] had RNA extracted from FFPE baseline liver biopsies. RNA with DV200 >10% underwent cDNA synthesis using Illumina TruSeq RNA followed by paired-end 150bp read sequencing on Illumina NovaSeq 6000. Only data that passed quality control (Qscore, AT/GC distribution, and error rate distribution) were subject to further analysis. FASTQ files had adapter sequences removed using cutadapt[35] and were then aligned to GRCh38 human reference genome using STAR[36]. Samtools[37] and featureCounts were used for sorting and counting. Log_2 transcripts per million (TPM) were used to compare JAG1, NOTCH1, HEYL, and HES expression between patients with mild (Ishak 0-2), moderate (Ishak 3-4), and severe fibrosis (Ishak 5-6) using Kruskal-Wallis test, with p-values adjusted for multiple testing. These results were replicated using the SteatoSITE MASLD transcriptomic dataset[38] available from https://shiny.igc.ed.ac.uk/SteatoSITE_gene_explorer/.

Immunohistochemistry (IHC)

IHC was performed on liver tissue from explants obtained at the time of transplant from patients with PSC, PBC, alcohol-related liver disease (ARLD), and MASLD, as well as healthy donor liver. The Queen Elizabeth Hospital in Birmingham is a major liver transplant centre performing more than 300 transplants per year. All samples used in this study were obtained as part of the routine biobanking of explanted (typically cirrhotic) liver tissue taken from transplants[39]. All liver tissue was obtained following informed consent, under the "Liver Inflammation" study (Research

Ethics Committee reference: 18/WA/0214; IRAS reference: 223072). Fresh tissue was formalin-fixed and paraffin-embedded (FFPE). FFPE sections were dewaxed in xylene then rehydrated in graded alcohols before heat antigen retrieval using Tris (Vector, H-3301) for 30 minutes. Endogenous peroxidase activity was blocked using BLOXALL (Vector, SP-6000-100) for 15 minutes at room temperature. Non-specific binding was blocked for 20 minutes at room temperature (Merck Millipore, 20773). Primary antibodies were incubated overnight at 4°C. Primary antibodies used were: JAG1 (Cell Signalling, D4Y1R, at 1/200), NOTCH2 (Cell Signalling, D76A6, at 1/50), and GBA1 (Abcam, EPR5142, at 1/200). Secondary antibodies (MP-7451 and MP-7452, Vector) were incubated for 1 hour at room temperature followed by developing with ImmPACT DAB (Vector, SK-4105) for 5 minutes and counter-stained with Mayers hematoxylin.

Immunofluorescence

Multiplex immunofluorescence was also performed on human liver FFPE samples. Antigen retrieval and blockade was performed as above. Each of four primary antibodies (JAG1, NOTCH2, CK19 (Abcam, Ab220193, at 1/1000), and ACTA2 (□-smooth muscle actin, Abcam, ab5694)) were incubated at room temperature for 1 hour. This was followed by 30 minutes of HRP-conjugated secondary antibody, as above, then 10-minutes development with tyramide signal amplification reagents: fluorescein (Akoya, NEL741001KT), Cy3 (Akoya, NEL744001KT), AZDye594 (CCT-1542), Cy5 (Akoya, NEL745001KT). Antibodies were stripped using Vectaplex (Vector, VRK-1000) for 15 minutes + 15 minutes at room temperature. Then blocking was repeated before the next primary antibody. Autofluorescence was quenched with TruView (Vector, SP-8400-15) and slides mounted with Vectashield with DAPI (Vector, H-1800). Images were acquired on a Zeiss LSM880 Confocal Microscope.

Statistical analysis

Integration of datasets was performed using R base functions and tidyverse. Genome-wide significance ($p<5x10^{-8}$) was used for initial identification of variant-trait associations with $p<0.05$ adjusted for multiple testing used throughout otherwise. All analyses were performed using R. Code is available from https://github.com/jmann01/MonogenicLiver.

Results

Monogenic liver disease genes demonstrate population-level associations

We identified 99 monogenic disorders that cause significant liver disease (Fig 1A & SupTab 1). Of these, 56% (55/99) had at least 'moderate' evidence of association with population-level liver-related traits using the HuGE calculator (Fig 1B) whilst 17% (17/99) were associated with at least two traits with 'very-strong' or 'compelling' evidence (Fig 1D & SupTab 2). This replicated well-established associations between *SERPINA1* (which causes alpha-1-antitrypsin deficiency) and *HFE* (which causes haemochromatosis) on ALT levels (Fig 1C). Genes that cause ductal plate malformations (e.g. *PKD1* and *PKHD1*) clustered together with genes that cause progressive familial intrahepatic cholestasis (e.g. *NR1H4*) due to associations with serum liver enzymes.

These findings were replicated using gene burden testing in the UK BioBank: 44% (44/99) of genes demonstrated at least one association (at p-FDR<0.05, Fig1E-F & SupTab 3). Similar patterns of gene-trait associations were demonstrated across pLoF, missense, and synonymous burden testing.

Common variants in monogenic disorder genes show genome-wide level associations with liver enzymes

We identified 82 independent variants associated with liver-related traits in 41% (41/99) of genes that cause 'monogenic' liver disease (Table 1 and SupTab 4). 84% (69/82) were common variants (>1% effect allele frequency).

Genome-wide significant associations were observed across all studied traits (Fig 2A). This replicated well-established associations between variants in *UGT1A1* (which causes Crigler-Najjar syndrome, as well as the more benign Gilbert's syndrome) and bilirubin. Where genes were associated with more than one phenotype (e.g. *ABCB4* was associated with GGT and ALT), colocalization analyses demonstrated that this was likely due to a single causal variant (Fig 2B-E & SupTab 5). For example, a single locus within *HNF1B* was associated with GGT, ALP, and albumin (Fig 2C).

Variants in genes that cause bile acid disorders, ductal plate malformations, and intrahepatic cholestasis predominantly had associations with indices of biliary disease (i.e. GGT, bilirubin, cholelithiasis, SupTab 4). For example, rs17855121T>C near *HSD3B7* (which causes 3β-hydroxy-Δ5-C27-steroid dehydrogenase deficiency, OMIM #607765) was associated with lower bilirubin levels (β (SE) = -0.015 (0.003), $p=3.0x10^{-8}$) and rs16961277A>G in *SLC10A2* (which causes Primary bile acid malabsorption 1, OMIM #613291) was associated with cholelithiasis and cholecystitis (β (SE) = -0.08 (0.012), $p=1.4x10^{-14}$).

24% (20/82) were protein-coding variants in the gene of interest. This included missense variants in *PKD1*: p.Pro36His, p.Arg1340Trp, p.Thr2250Met, p.Arg2765Cys, all of which affect 1 in 500-700 individuals and therefore are too common to cause autosomal dominant polycystic

kidney disease in isolation. All these variants are associated with GGT and/or ALP at genome-wide significance (all $p \leq 2.9 \times 10^{-9}$,SupTab 4).

Three missense variants (p.Val417Ile, p.Gly921Ser, p.Val1188Glu) in *ABCC2* (which causes Dubin-Johnson syndrome) were associated with multiple indices of liver injury: ALT, AST, GGT, and (conjugated) bilirubin (all $p \leq 3.6 \times 10^{-9}$).

For the non-coding variants, 44% (27/62) had a significant eQTL for the gene of interest (SupTab 4). For example, an intronic variant in *HNF1B* (which causes the dominant disorder Renal cysts and diabetes syndrome, OMIM #137920) was associated with liver-specific eQTL for *HNF1B* ($p=6.0 \times 10^{-3}$) and genome-wide associations in albumin, ALT, AST, GGT, cholelithiasis, and cholecystitis (all $p \leq 3.2 \times 10^{-8}$).

Within genes there is a dose-effect response, with more severe loss-of-function variants having greater effect sizes. Data from rare variant analysis on the Common Metabolic Disease Knowledge Portal demonstrates that, pooling 53 loss of function (LoF) variants in *ABCB4* are associated with higher ALT with nearly 10-fold greater effect size compared to pooling of 511 missense variants ($\beta = 0.026$ LoF versus $\beta = 0.0024$ for missense). Similarly, 100 LoF variants in ABCC2 on direct bilirubin had about 10 times the effect size compared to 647 missense variants ($\beta = 0.011$ LoF versus $\beta = 0.0019$ for missense).

The magnitude of effect of these variants is smaller than well-established common variants that influence liver disease. For example, rs41318029:G>A in *ABCC2* was associated with GGT with $\beta = 0.06$, whilst, a common variant in *GGT1* (rs3859862:A>G, effect allele frequency = 0.42) has more than three times the effect size with $\beta = 0.21$. Similarly, rs1047891:C>A in *CPS1* is associated with higher ALT with $\beta = 0.04$, whereas the well-established variant in *PNPLA3* rs738409:C>G has again three times the effect size at $\beta = 0.15$.

Overall, this demonstrates that common variants in genes that cause monogenic liver disease are associated with indices of liver injury.

Variants in five genes validated with clinical liver disease outcomes

Next, we sought to validate individual variants in independent cohorts of adults with clinically significant liver disease.

Using six GWAS in patients with liver disease we established that variants in five genes (*ABCC2*, *ASL*, *BCS1L*, *HFE*, and *SERPINA1*) were associated with at least one clinical liver disease (SupTab 6 & Table 1). This included the well-established all-cause cirrhosis risk variants in *SERPINA1* and *HFE*[29,30].

Cumulative burden of variants in monogenic disorder genes affect risk of chronic liver disease

We extended these observations by replication in the All of Us cohort in nearly 350,00 individuals. 35 out of 82 independent variants were present in the All of Us dataset and we replicated variant-trait association across 57% (20/35) variants (SupTab 7).

Then we created an unweighted polygenic risk score (PRS) using the number of effect alleles across all 35 variants. Consistent with the effect direction observed in the original discovery, higher PRS quartile was associated with lower levels of ALP, ALT, and AST, but higher total and conjugated bilirubin (Table 2). The effect sizes are small: from highest to lowest quartile there is 0.1 IU/L difference in ALT and ALP. However this translated into a significant negative association with diagnosis of MASLD (β (SE) = -0.0116 (0.0031), $p=1.7x10^{-4}$) or any chronic liver disease (β (SE) = -0.0050 (0.0022), p=.02) after adjusting for age, sex, and BMI (Figure 3 and SupTab8). Between PRS

Monogenic disorder genes show expression changes in MASLD and PSC progression

Given that most variants identified in our analysis were non-coding, we hypothesised that they may be acting through gene dosage. Therefore, we determined whether expression of these genes change with severity of liver disease using n=216 individuals with MASLD. 38% of genes (26/94) demonstrated variance with severity of MASLD (Fig 4 & SupTab 9). Specifically, 30% (28/94) showed differential expression between patients with MASL and MASH cirrhosis. This included upregulation and downregulation of genes across multiple different pathways (e.g. *DCDC2*, *HNF1B*, *HJV*). The top differentially expressed gene was *JAG1* (Fig 4E, log2FC 1.6, p.adj = $2.9x10^{-13}$). This finding was replicated in primary sclerosing cholangitis *JAG1* (Fig 4I and SupFig 1) and an additional MASLD cohort (Fig 4J).

JAG1-NOTCH signalling localises to ductular reaction in chronic liver disease

Our analyses found multiple variants in *JAG1* associated with indices of liver injury in adults as well as transcriptionally associated with stage of liver disease. Therefore, we next performed immunohistochemistry to visualise how JAG1-NOTCH signalling is perturbed in chronic liver disease. JAG1 is expressed in arterial structures in healthy adult liver (Fig 5A). However, it becomes strongly expressed in regenerative biliary ductules as part of the ductular reaction, most evident in cholangiopathies but also in ARLD, as previously reported[40]. NOTCH2 was not readily detectable in healthy liver but widely expressed throughout fibrotic areas and reactive ductules in cirrhosis (Fig 5B). Using multiplex immunohistochemistry, we found that JAG1 and NOTCH2 are co-expressed on injured biliary epithelial cells ($CK19^{+}$ SMA^{+}) in PSC and PBC but not on adjacent unaffected ducts (Fig 5C). In addition, NOTCH2 was expressed on a subset of SMA^{+} fibroblasts within fibrotic regions.

Discussion

Since the widespread use of next generation sequencing, it has become clear that onset and severity of acquired liver diseases (e.g. steatotic liver disease, viral hepatitis) are influenced by germline variation[30,41]. However, these were generally thought to be distinct from the pathways perturbed by rare, loss-of-function variants that lead to early onset severe phenotypes. Building on work done by others[42], we have demonstrated that common variation in such genes impacts the onset and severity of liver disease in adults. Understanding the pathways implicated in rare, paediatric liver disease may lead to novel therapeutic targets[43].

It has long been recognised that there is wide phenotypic variation in apparently monogenic disorders[2]. For example, it is not uncommon to have a child with Alagille syndrome affected with profound cholestasis whilst their parent is asymptomatic, despite both harbouring the same variant. Therefore, such pathways are subject to gene-environment interactions, as are other genes where common variants affect liver phenotypes (e.g. *PNPLA3*)[44]. For example, obesity and insulin resistance leading to steatosis promote liver injury in the context of variants that perturb hepatocyte metabolic function (e.g. *LIPA*, where common variants are associated with ALT in this study).

JAG1-NOTCH signalling is a key component of the ductular reaction, being specifically expressed in injured bile ducts, as well as playing a role in liver regeneration in mice[40]. Our observations are consistent with previous murine models showing the role of JAG1-NOTCH in the ductular reaction in steatohepatitis[45,46]. Collectively, the JAG1-NOTCH signalling is one example of how a pathway typically thought of to cause exclusively rare liver disease in early childhood is involved in adult liver disorders.

The concept of 'monogenic' disease has been progressively eroded across liver disease[9,42] and other fields[47]. For example, variation in genes that cause monogenic developmental disorders cause more mild phenotypes of the same conditions in the general population[48]. Similarly, for coronary artery disease, genome-wide polygenic risk scores have shown that individuals in the top decile of polygenic risk have a disease incidence comparable to that of 'monogenic' familial hypercholesterolaemia[49]. This study has illustrated that a similar principle applies for liver disease: the phenotype that affects patients is a combination of polygenic risk (from both rare and common variants) plus environmental factors, even for conditions typically thought of as exclusively genetic or acquired.

These data help in prioritisation of genes for potential therapy and insights into disease mechanisms by integration of these genetic associations with known biological function. For example, *HNF1B* is a promising candidate to investigate the mechanism biliary disorders (e.g. PSC): loss of function variants in *HNF1B* lead to ductal plate malformations, variants in this gene are associated metrics of biliary injury, and its expression is enriched in cholangiocytes[50]. Similarly, *GALK* may be a candidate for steatotic liver disease, given that loss of function variants cause parenchymal injury, variants in *GALK* are associated with ALT, and it is

expressed in hepatocytes[50]. GALK inhibitors are already in development for the treatment of classical galactosemia due to the effect of GALK in generating toxic galactose-1-phosphate[51].

Identification of such effects requires large studies to demonstrate small effect sizes. Overall the effect sizes appear to be about a third compared to common, well-established genome-wide significant variants (e.g. *PNPLA3*). Therefore, it is hard to quantify how these observations influence the phenotype of common liver diseases at an individual patient-level. We observed several variants to reduce the risk of liver diseases, the mechanism of which has not been identified at this time Therefore to elucidate gene- and variant-specific mechanisms will require careful functional studies with cellular stressors.

Conclusion

Most genes that cause severe monogenic paediatric liver disease are associated with liver injury in adults. The JAG1-NOTCH pathway is a key component of the ductular reaction that is affected by common variation and associated with disease severity in cirrhosis. These findings challenge the notion of 'monogenic' liver disease and underscore the potential to pharmacologically target the pathways implicated in rare liver diseases for treatment of common diseases in adults.

Figure legends

Fig 1. Genes that cause monogenic liver disease are associated with liver-related traits at a population level. (A) Summary of the study design. (B) Proportion of genes with at least 'moderate' evidence for liver-related traits based on HuGE score (Human Genetic Evidence score from the Knowledge Portal Network). (C) Proportion of genes with each level of evidence for liver-related traits based on HuGE score. (D) Heatmap showing standard deviations of HuGE score (normalised by trait) and level of evidence for liver-related traits: * = Moderate, ** = Strong, *** = Very strong, **** = Compelling. (E-F) Heatmap results from gene burden testing on GeneBass showing standard deviations of beta for association for binary (E) and continuous (F) traits, annotated with pFDR: * ≤.05, ** ≤.01, *** ≤.001, *** ≤.0001. ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARLD, alcohol-related liver disease; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; MASLD, metabolic-dysfunction-associated steatotic liver disease.

Fig 2. Common variants in genes that cause monogenic disease are associated with liver-related traits. Dot plot showing individual variants P-values for liver-related traits, with annotation of a selection of top genes (A). Y-axis is $\log_{10}(-\log_{10}(\text{p-values}))$ scaled. LocusZoom plots from Common Metabolic Disease Knowledge Portal Data demonstrating associations for *ABCB4* (B), *HNF1B* (C), *ATP8B1* (D), and *CPS1* (E).

Fig 3. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in the All of Us study, stratified by monogenic polygenic risk score (PRS). PRS was calculated as the sum of alternate alleles (without weighting) for all 35 variants present in the dataset. P-value was derived using multivariable logistic regression in n=346,332 individuals dataset for the presence of MASLD against (PRS), adjusted for age and sex.

Fig 4. Expression of genes that cause monogenic disease is associated with severity of MASLD. Violin plots showing normalised gene expression across the spectrum of MASLD (n=216) from GSE135251 for *DCDC2* (A), *HJV* (B), *CYP27A1* (C), *GALK1* (D), *JAG1* (E), *NOTCH2* (F), *AKR1D1* (G), and *HNF1B* (H). p.adj represent differential gene expression between MASL and MASH F4 groups. Association of *JAG1* transcripts with fibrosis stage in PSC[34] (E) and MASLD[38] (F).

Fig 5. JAG1-NOTCH expression on injured bile ducts affects severity of PSC. Expression of JAG1 and NOTCH2 in normal liver, PSC, PBC, and ARLD on immunohistochemistry (A-B, representative of n=5 patients per condition). Multiplex immunofluorescence showing expression of JAG1, NOTCH2, □SMA (ACTA2), and CK19, in human liver tissue (C, representative of n=5 patients per condition).

Table legends

Table 1. Variant-trait associations in genes that also cause monogenic liver disease. Variants are annotated with: predicted protein functional effect (from Ensembl's Variant Effect Predictor), liver tissue eQTL data from GTEx, effect allele frequency (EAF) from gnomAD, and results from replication across six cohorts of patients with clinical liver disease.

Supplementary data

SupTab 1. Genes included in this study and their respective disorders with Online Mendelian Inheritance in Man (OMIM) identifiers.

SupTab 2. HuGE scores and evidence levels for all genes and traits included in this study.

SupTab 3. GeneBass burden testing (pLoF, missense, and synonymous) for all genes and traits included in this study.

SupTab 4. Summary of all variant-trait associations identified in this study. Variants are annotated with: predicted protein functional effect (from Ensembl's Variant Effect Predictor) and liver tissue eQTL data from GTEx.

SupTab 5. Results from colocalization analyses using data from Sakaue et al. for plots displayed in Figure 2B. Posterior probability results: PP.H0.abf = neither trait has a causal variant in the region; PP.H1.abf = only trait 1 has a causal variant; PP.H2.abf = only trait 2 has a causal variant; PP.H3.abf = both traits have a significant association but the causal variants are different; and PP.H4.abf = both traits have a significant association share the same causal variant. PP.H4.abf >0.8 was described as “Strong” evidence of colocalization.

SupTab 6. Summary of all results from validation of variants in external cohorts.

SupTab 7. Variant-trait associations present in the All of Us dataset. Only significant associations are shown (using Bonferroni adjusted p-value cut-off of 0.05/35 = .0014).

SupTab 8. Results from multivariable logistic regression in the All of Us dataset for the presence of liver disease against monogenic probability risk score (PRS), adjusted for age and sex. PRS was calculated as the sum of alternate alleles for all 35 variants present in the All of Us dataset.

SupTab 9. Results from ANOVA and F0 vs F4 from GSE135251: transcriptomic profiling across the spectrum of MASLD.

SupFig 1. Hepatic expression of JAG1, NOTCH1, HEYL, and HES1 in patients with PSC grouped by Ishak fibrosis stage, collagen deposition, ELF score, and ALP level. Whiskers extend to the minimum and maximum values of the data set. p values are based on the Kruskal–Wallis test. ALP, alkaline phosphatase; ELF, enhanced liver fibrosis; TPM, transcripts per million.

References

1. Baumann U, Karam V, Adam R, Fondevila C, Dhawan A, Sokal E, Jacquemin E, Kelly DA, Grabhorn E, Pawlowska J, D'Antiga L, Jara Vega P, Debray D, Polak WG, de Ville de Goyet J, Verkade HJ, European Liver and Intestine Transplant Association (ELITA) and all ELTR contributing centers. Prognosis of Children Undergoing Liver Transplantation: A 30-Year European Study. Pediatrics;150 . Epub ahead of print October 1, 2022. DOI: 10.1542/peds.2022-057424.

2. Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N. Systematic review: The epidemiology, natural history, and burden of alagille syndrome. J Pediatr Gastroenterol Nutr 2018;67:148–156.

3. Gao J, Brackley S, Mann JP. The global prevalence of Wilson disease from next-generation sequencing data. Genet Med 2019;21:1155–1163.

4. van Wessel DBE, Thompson RJ, Gonzales E, Jankowska I, Sokal E, Grammatikopoulos T, Kadaristiana A, Jacquemin E, Spraul A, Lipiński P, Czubkowski P, Rock N, Shagrani M, Broering D, Algoufi T, Mazhar N, Nicastro E, Kelly DA, Nebbia G, Arnell H, Björn Fischler, Hulscher JBF, Serranti D, Arikan C, Polat E, Debray D, Lacaille F, Goncalves C, Hierro L, Muñoz Bartolo G, Mozer-Glassberg Y, Azaz A, Brecelj J, Dezsőfi A, Calvo PL, Grabhorn E, Sturm E, van der Woerd WJ, Kamath BM, Wang J-S, Li L, Durmaz Ö, Onal Z, Bunt TMG, Hansen BE, Verkade HJ, NAtural course and Prognosis of PFIC and Effect of biliary Diversion (NAPPED) consortium. Genotype correlates with the natural history of severe bile salt export pump deficiency. J Hepatol 2020;73:84–93.

5. Peltonen L, Perola M, Naukkarinen J, Palotie A. Lessons from studying monogenic disease for common disease. Hum Mol Genet 2006;15 Spec No 1:R67-74.

6. Chen VL, Chen Y, Du X, Handelman SK, Speliotes EK. Genetic variants that associate with

cirrhosis have pleiotropic effects on human traits. Liver Int 2020;40:405–415.

7. Schwantes-An T-H, Darlay R, Mathurin P, Masson S, Liangpunsakul S, Mueller S, Aithal GP, Eyer F, Gleeson D, Thompson A, Muellhaupt B, Stickel F, Soyka M, Goldman D, Liang T, Lumeng L, Pirmohamed M, Nalpas B, Jacquet J-M, Moirand R, Nahon P, Naveau S, Perney P, Botwin G, Haber PS, Seitz HK, Day CP, Foroud TM, Daly AK, Cordell HJ, Whitfield JB, Morgan TR, Seth D, GenomALC Consortium. Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors. Hepatology 2021;73:1920–1931.

8. Grammatikopoulos T, Sambrotta M, Strautnieks S, Foskett P, Knisely AS, Wagner B, Deheragoda M, Starling C, Mieli-Vergani G, Smith J, University of Washington Center for Mendelian Genomics, Bull L, Thompson RJ. Mutations in DCDC2 (doublecortin domain containing protein 2) in neonatal sclerosing cholangitis. J Hepatol 2016;65:1179–1187.

9. Hegarty R, Gurra O, Tarawally J, Allouni S, Rahman O, Strautnieks S, Kyrana E, Hadzic N, Thompson RJ, Grammatikopoulos T. Clinical outcomes of ABCB4 heterozygosity in infants and children with cholestatic liver disease. J Pediatr Gastroenterol Nutr 2024;78:339–349.

10. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–424.

11. Amberger JS, Bocchini CA, Scott AF, Hamosh A. Omim.org: leveraging knowledge across phenotype-gene relationships. Nucleic Acids Res 2019;47:D1038–D1043.

12. Dornbos P, Singh P, Jang D-K, Mahajan A, Biddinger SB, Rotter JI, McCarthy MI, Flannick

J. Evaluating human genetic support for hypothesized metabolic disease genes. Cell Metab 2022;34:661–666.

13. Karczewski KJ, Solomonson M, Chao KR, Goodrich JK, Tiao G, Lu W, Riley-Gillis BM, Tsai EA, Kim HI, Zheng X, Rahimov F, Esmaeeli S, Grundstad AJ, Reppell M, Waring J, Jacob H, Sexton D, Bronson PG, Chen X, Hu X, Goldstein JI, King D, Vittal C, Poterba T, Palmer DS, Churchhouse C, Howrigan DP, Zhou W, Watts NA, Nguyen K, Nguyen H, Mason C, Farnham C, Tolonen C, Gauthier LD, Gupta N, MacArthur DG, Rehm HL, Seed C, Philippakis AA, Daly MJ, Davis JW, Runz H, Miller MR, Neale BM. Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. Cell Genom 2022;2:100168.

14. Ghoussaini M, Mountjoy E, Carmona M, Peat G, Schmidt EM, Hercules A, Fumis L, Miranda A, Carvalho-Silva D, Buniello A, Burdett T, Hayhurst J, Baker J, Ferrer J, Gonzalez-Uriarte A, Jupp S, Karim MA, Koscielny G, Machlitt-Northen S, Malangone C, Pendlington ZM, Roncaglia P, Suveges D, Wright D, Vrousgou O, Papa E, Parkinson H, MacArthur JAL, Todd JA, Barrett JC, Schwartzentruber J, Hulcoop DG, Ochoa D, McDonagh EM, Dunham I. Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. Nucleic Acids Res 2021;49:D1311–D1320.

15. Perez G, Barber GP, Benet-Pages A, Casper J, Clawson H, Diekhans M, Fischer C, Gonzalez JN, Hinrichs AS, Lee CM, Nassar LR, Raney BJ, Speir ML, van Baren MJ, Vaske CJ, Haussler D, Kent WJ, Haeussler M. The UCSC Genome Browser database: 2025 update. Nucleic Acids Res 2025;53:D1243–D1249.

16. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, Flicek P, Cunningham F. The Ensembl Variant Effect Predictor. Genome Biol 2016;17:122.

17. Boughton AP, Welch RP, Flickinger M, VandeHaar P, Taliun D, Abecasis GR, Boehnke M. LocusZoom.js: interactive and embeddable visualization of genetic association study results. Bioinformatics 2021;37:3017–3018.

18. Kerimov N, Hayhurst JD, Peikova K, Manning JR, Walter P, Kolberg L, Samoviča M, Sakthivel MP, Kuzmin I, Trevanion SJ, Burdett T, Jupp S, Parkinson H, Papatheodorou I, Yates AD, Zerbino DR, Alasoo K. A compendium of uniformly processed human gene expression and splicing quantitative trait loci. Nat Genet 2021;53:1290–1299.

19. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, Narita A, Konuma T, Yamamoto K, Akiyama M, Ishigaki K, Suzuki A, Suzuki K, Obara W, Yamaji K, Takahashi K, Asai S, Takahashi Y, Suzuki T, Shinozaki N, Yamaguchi H, Minami S, Murayama S, Yoshimori K, Nagayama S, Obata D, Higashiyama M, Masumoto A, Koretsune Y, FinnGen, Ito K, Terao C, Yamauchi T, Komuro I, Kadowaki T, Tamiya G, Yamamoto M, Nakamura Y, Kubo M, Murakami Y, Yamamoto K, Kamatani Y, Palotie A, Rivas MA, Daly MJ, Matsuda K, Okada Y. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet 2021;53:1415–1424.

20. Murphy AE, Schilder BM, Skene NG. MungeSumstats: a Bioconductor package for the standardization and quality control of many GWAS summary statistics. Bioinformatics 2021;37:4593–4596.

21. Lyon MS, Andrews SJ, Elsworth B, Gaunt TR, Hemani G, Marcora E. The variant call format provides efficient and robust storage of GWAS summary statistics. Genome Biol 2021;22:32.

22. Guo H, Fortune MD, Burren OS, Schofield E, Todd JA, Wallace C. Integration of disease association and eQTL data using a Bayesian colocalisation approach highlights six

candidate causal genes in immune-mediated diseases. Hum Mol Genet 2015;24:3305–3313.

23. Breeze CE, Haugen E, Gutierrez-Arcelus M, Yao X, Teschendorff A, Beck S, Dunham I, Stamatoyannopoulos J, Franceschini N, Machiela MJ, Berndt SI. FORGEdb: a tool for identifying candidate functional variants and uncovering target genes and mechanisms for complex diseases. Genome Biol 2024;25:3.

24. The 1000 Genomes Project Consortium. A global reference for human genetic variation. Nature 2015;526:68–74.

25. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015;4:7.

26. Ji S-G, Juran BD, Mucha S, Folseraas T, Jostins L, Melum E, Kumasaka N, Atkinson EJ, Schlicht EM, Liu JZ, Shah T, Gutierrez-Achury J, Boberg KM, Bergquist A, Vermeire S, Eksteen B, Durie PR, Farkkila M, Müller T, Schramm C, Sterneck M, Weismüller TJ, Gotthardt DN, Ellinghaus D, Braun F, Teufel A, Laudes M, Lieb W, Jacobs G, Beuers U, Weersma RK, Wijmenga C, Marschall H-U, Milkiewicz P, Pares A, Kontula K, Chazouillères O, Invernizzi P, Goode E, Spiess K, Moore C, Sambrook J, Ouwehand WH, Roberts DJ, Danesh J, Floreani A, Gulamhusein AF, Eaton JE, Schreiber S, Coltescu C, Bowlus CL, Luketic VA, Odin JA, Chopra KB, Kowdley KV, Chalasani N, Manns MP, Srivastava B, Mells G, Sandford RN, Alexander G, Gaffney DJ, Chapman RW, Hirschfield GM, de Andrade M, UK-PSC Consortium, International IBD Genetics Consortium, International PSC Study Group, Rushbrook SM, Franke A, Karlsen TH, Lazaridis KN, Anderson CA. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet 2017;49:269–273.

27. Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y, Kawashima M, Nishida N, Khor S-S, Gervais O, Kawai Y, Nagasaki M, Tokunaga K, Tang R, Shi Y, Li Z, Juran BD, Atkinson EJ, Gerussi A, Carbone M, Asselta R, Cheung A, de Andrade M, Baras A, Horowitz J, Ferreira MAR, Sun D, Jones DE, Flack S, Spicer A, Mulcahy VL, Byan J, Han Y, Sandford RN, Lazaridis KN, Amos CI, Hirschfield GM, Seldin MF, Invernizzi P, Siminovitch KA, Ma X, Nakamura M, Mells GF, PBC Consortia, Canadian PBC Consortium, Chinese PBC Consortium, Italian PBC Study Group, Japan-PBC-GWAS Consortium, US PBC Consortium, UK-PBC Consortium. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. J Hepatol 2021;75:572–581.

28. Chen Y, Du X, Kuppa A, Feitosa MF, Bielak LF, O'Connell JR, Musani SK, Guo X, Kahali B, Chen VL, Smith AV, Ryan KA, Eirksdottir G, Allison MA, Bowden DW, Budoff MJ, Carr JJ, Chen Y-DI, Taylor KD, Oliveri A, Correa A, Crudup BF, Kardia SLR, Mosley TH Jr, Norris JM, Terry JG, Rotter JI, Wagenknecht LE, Halligan BD, Young KA, Hokanson JE, Washko GR, Gudnason V, Province MA, Peyser PA, Palmer ND, Speliotes EK. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat Genet 2023;55:1640–1650.

29. Emdin CA, Haas M, Ajmera V, Simon TG, Homburger J, Neben C, Jiang L, Wei W-Q, Feng Q, Zhou A, Denny J, Corey K, Loomba R, Kathiresan S, Khera AV. Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene-Environment Interaction Study. Gastroenterology 2021;160:1620-1633.e13.

30. Ghouse J, Sveinbjörnsson G, Vujkovic M, Seidelin A-S, Gellert-Kristensen H, Ahlberg G, Tragante V, Rand SA, Brancale J, Vilarinho S, Lundegaard PR, Sørensen E, Erikstrup C, Bruun MT, Jensen BA, Brunak S, Banasik K, Ullum H, DBDS Genomic Consortium, Verweij N, Lotta L, Baras A, Regeneron Genetics Center, Mirshahi T, Carey DJ, Geisinger-

Regeneron DiscovEHR Collaboration, VA Million Veteran Program, Kaplan DE, Lynch J, Morgan T, Schwantes-An T-H, Dochtermann DR, Pyarajan S, Tsao PS, Estonian Biobank Research Team, Laisk T, Mägi R, Kozlitina J, Tybjærg-Hansen A, Jones D, Knowlton KU, Nadauld L, Ferkingstad E, Björnsson ES, Ulfarsson MO, Sturluson Á, Sulem P, Pedersen OB, Ostrowski SR, Gudbjartsson DF, Stefansson K, Olesen MS, Chang K-M, Holm H, Bundgaard H, Stender S. Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis. Nat Genet 2024;56:827–837.

31. All of Us Research Program Investigators, Denny JC, Rutter JL, Goldstein DB, Philippakis A, Smoller JW, Jenkins G, Dishman E. The “All of Us” Research Program. N Engl J Med 2019;381:668–676.

32. GitHub - hail-is/hail: Cloud-native genomic dataframes and batch computing. *GitHub* Available from: https://github.com/hail-is/hail. Accessed December 1, 2025.

33. Govaere O, Cockell S, Tiniakos D, Queen R, Younes R, Vacca M, Alexander L, Ravaioli F, Palmer J, Petta S, Boursier J, Rosso C, Johnson K, Wonders K, Day CP, Ekstedt M, Orešič M, Darlay R, Cordell HJ, Marra F, Vidal-Puig A, Bedossa P, Schattenberg JM, Clément K, Allison M, Bugianesi E, Ratziu V, Daly AK, Anstee QM. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Sci Transl Med 2020;12:eaba4448.

34. Muir AJ, Levy C, Janssen HLA, Montano-Loza AJ, Shiffman ML, Caldwell S, Luketic V, Ding D, Jia C, McColgan BJ, McHutchison JG, Mani Subramanian G, Myers RP, Manns M, Chapman R, Afdhal NH, Goodman Z, Eksteen B, Bowlus CL, GS-US-321-0102 Investigators. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease. Hepatology 2019;69:684–698.

35. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 2011;17:10–12.

36. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013;29:15–21.

37. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, Whitwham A, Keane T, McCarthy SA, Davies RM, Li H. Twelve years of SAMtools and BCFtools. Gigascience;10 . Epub ahead of print February 16, 2021. DOI: 10.1093/gigascience/giab008.

38. Kendall TJ, Jimenez-Ramos M, Turner F, Ramachandran P, Minnier J, McColgan MD, Alam M, Ellis H, Dunbar DR, Kohnen G, Konanahalli P, Oien KA, Bandiera L, Menolascina F, Juncker-Jensen A, Alexander D, Mayor C, Guha IN, Fallowfield JA. An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease. Nat Med 2023;29:2939–2953.

39. Oo YH, Weston CJ, Lalor PF, Curbishley SM, Withers DR, Reynolds GM, Shetty S, Harki J, Shaw JC, Eksteen B, Hubscher SG, Walker LSK, Adams DH. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol 2010;184:2886–2898.

40. Boulter L, Govaere O, Bird TG, Radulescu S, Ramachandran P, Pellicoro A, Ridgway RA, Seo SS, Spee B, Van Rooijen N, Sansom OJ, Iredale JP, Lowell S, Roskams T, Forbes SJ. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med 2012;18:572–579.

41. Tamaki N, Ahlholm N, Luukkonen PK, Porthan K, Sharpton SR, Ajmera V, Kono Y, Dave S, Ahmed A, Sundaram V, Wilkinson MJ, Patton H, Gupta H, Cervantes V, Hernandez C, Lopez SJ, Loomba R, Baumgartner A, Richards L, Arkkila PE, Nemes K, Isoniemi H, Yki-

Järvinen H, Loomba R. Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. J Clin Invest;132 . Epub ahead of print November 1, 2022. DOI: 10.1172/JCI162513.

42. Nayagam JS, Foskett P, Strautnieks S, Agarwal K, Miquel R, Joshi D, Thompson RJ. Clinical phenotype of adult-onset liver disease in patients with variants in ABCB4, ABCB11, and ATP8B1. Hepatol Commun 2022;6:2654–2664.

43. Brinkman RR, Dubé M-P, Rouleau GA, Orr AC, Samuels ME. Human monogenic disorders - a source of novel drug targets. Nat Rev Genet 2006;7:249–260.

44. Stender S, Kozlitina J, Nordestgaard BG, Tybjærg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 2017;EPub 24 April 2017.

45. Yu J, Zhu C, Wang X, Kim K, Bartolome A, Dongiovanni P, Yates KP, Valenti L, Carrer M, Sadowski T, Qiang L, Tabas I, Lavine JE, Pajvani UB. Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis. Sci Transl Med;13 . Epub ahead of print June 23, 2021. DOI: 10.1126/scitranslmed.abe1692.

46. Morell CM, Fiorotto R, Meroni M, Raizner A, Torsello B, Cadamuro M, Spagnuolo G, Kaffe E, Sutti S, Albano E, Strazzabosco M. Notch signaling and progenitor/ductular reaction in steatohepatitis. PLoS One 2017;12:e0187384.

47. Jacob E, Hegele RA. Monogenic versus polygenic forms of hypercholesterolemia and cardiovascular risk: Are there any differences? Curr Atheroscler Rep 2022;24:419–426.

48. Kingdom R, Beaumont RN, Wood AR, Weedon MN, Wright CF. Genetic modifiers of rare variants in monogenic developmental disorder loci. Nat Genet 2024;56:861–868.

49. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT, Kathiresan S. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 2018;50:1219–1224.

50. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Björling L, Ponten F. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010;28:1248–1250.

51. Tang M, Wierenga K, Elsas LJ, Lai K. Molecular and biochemical characterization of human galactokinase and its small molecule inhibitors. Chem Biol Interact 2010;188:376–385.


A
1 Gene identification
99 genes causing severe paediatric liver disease
2 Gene-level analysis
HuGE calculator + burden testing
99 genes
1.6 million
Liver & non-liver traits
3 Variant-level analysis
CMDKP
Open Targets
genebass
eQTL
VEP
Replication in disease-specific cohorts
4 Gene characterisation in adult chronic liver disease
RNA expression in MASLD and PSC
Immunohistochemistry
Results
1. Genome-wide significant associations in 41/99 genes
2. Expression associated with fibrosis stage in 26/94 genes
3. JAG1-NOTCH2 signalling contributes to ductular reaction
B
0 traits, 37 genes
1 traits, 20 genes
2 traits, 9 genes
3 traits, 8 genes
4 traits, 7 genes
5 traits, 6 genes
6 traits, 3 genes
7 traits, 1 genes
8 traits, 1 genes
C
Percentage of genes
100%
80%
60%
40%
Direct bilirubin
AST:ALT ratio
Albumin
Bilirubin
AST
ALT
GGT
ALP
Cirrhosis
Level of evidence
Compelling
Very Strong
Strong
Moderate
Anecdotal
No Evidence
D
HuGE score
ABCC2
SERPINA1
UGT1A1
LIPA
JAG1
KIF12
HSD3B7
TFR2
GALK1
PEX26
ALG8
TWNK
MARS1
MPV17
PKD2
MPI
SEC63
NR1H4
PKD1
ABCB11
NPC1
PKHD1
ABCB4
HFE
ATP8B1
HNF1B
Bilirubin
Direct Bilirubin
Albumin
NAFLD
AST:ALT ratio
Cirrhosis
ALP
ALT
GGT
AST
E
Beta
NPC1
EIF2AK3
SLC40A1
ABCB4
ABCC2
AGL
SCO1
ATP8B1
SEC63
ABCB11
AMACR
Viral Hepatitis
Cirrhosis
Hepatitis
ARLD
Cholecystitis
Cholelithiasis
Biliary disease
F
Beta
TJP2
NR1H4
SEC63
TWNK
ABCB11
PEX26
SLC25A13
PKD1
GBA
ATP8B1
PKHD1
UGT1A1
G6PC
ABCC2
UTP4
DGUOK
PKD2
HAMP
ABCB4
SLC10A2
GGT
AST
Bilirubin
Direct bilirubin
ALP
Alb
ALT


A
P-value
2.4x10-317
1.0x10-100
2.4x10-32
1.0x10-10
neglog_p
300
200
100
DCDC2
ALDOB
ABCB11
ASS1
SERPINA1
HFE
PKD1
NPC2
CPS1
PAH
BCS1L
UGT1A1
PEX26
ABCC2
PKD1
ATP8B1
HNF1B
SERPINA1
ABCB11
BCS1L
NOTCH2
ABCC2
SERPINA1
ABCB4
ATP8B1
ABCB11
HNF1B
CPS1
PEX6
GALK1
ABCC2
SERPINA1
AHI1
ABCB11
HFE
ABCB4
CPS1
UGT1A1
UGT1A1
HFE
CPS1
PEX6
ABCC2
UGT1A1
UGT1A1
HFE
ABCC2
GALK1
SERPINA1
SERPINA1
HMBS
HNF1B
AHI1
MPI
PEX26
ALP
GGT
ALT
AST
Cholelithiasis
Bilirubin
Direct bilirubin
Albumin
B
Gamma-glutamyl transferase (GGT)
Alanine transaminase (ALT)
Total bilirubin
-log10 p-value
Recombination Rate (cM/Mb)
Chromosome 7 (Mb)
CROT→
←ABCB1
←ABCB4
RUNDC3B→
C
Gamma-glutamyl transferase (GGT)
Alkaline phosphatase (ALP)
Serum albumin
Chromosome 17 (Mb)
TADA2A→
DUSP14→
←DDX52
←HNF1B
←SYNRG
D
Direct bilirubin
Aspartate aminotransferase (AST)
Gamma-glutamyl transferase (GGT)
LD Ref Var
1.0 > r² ≥ 0.8
0.8 > r² ≥ 0.6
0.6 > r² ≥ 0.4
0.4 > r² ≥ 0.2
0.2 > r² ≥ 0.0
no r² data
Chromosome 18 (Mb)
←FECH
←NARS1
←ATP8B1
E
Alanine transaminase (ALT)
Alkaline phosphatase (ALP)
Total bilirubin
Chromosome 2 (Mb)
←LANCL1
CPS1→


p=1.7x10-4
β (SE) = -0.012 (0.003)
Fewest effect alleles
Most effect alleles
% of individuals with MASLD
5.2
5.1
5.0
4.9
4.8
4.7
4.6
4.5
1
2
3
4
5
6
7
8
Monogenic variant probability risk score group


A
DCDC2
p.adj=6.4x10-13
B
HJV
p.adj=2.1x10-5
C
CYP27A1
p.adj=8.5x10-4
D
GALK1
p.adj=1.2x10-3
E
JAG1
p.adj=2.9x10-13
F
NOTCH2
p.adj=.31
G
AKR1D1
p.adj=6.3x10-7
H
HNF1B
p.adj=.003
Expression
Control
NAFL
NASH F1
NASH F2
NASH F3
NASH F4
I
JAG1 in PSC
p<0.001
Log2(TPM)
Ishak 0–2 (n=42)
Ishak 3–4 (n=22)
Ishak 5–6 (n=11)
J
JAG1
p.adj=2.1x10-32
Log2CPM
Control
F0-F1
F2
F3
F4


A
JAG1
Control
PBC
PSC
ARLD
200μm
B
NOTCH2
Control
PBC
PSC
ARLD
200μm
C
JAG1
NOTCH2
ACTA2
CK19
DAPI
Merge
Control
ARLD
PSC
PBC
50μm

Gene	SNP	Variant	EAF	Variant	eQTL	Phenotypes (p)	Clinical outcomes (p-FDR)
ABCB4	rs17149637	7_87462869_G_A	0.252396	ABCB4 (p.Leu59=)	Multiple	ALT: - (5.5x10-26), AST: - (4.6x10-8)	
ABCC2	rs2862926	10_100057584_A_G	0.303315	Intergenic	-	ALT: - (3.0x10-61), AST: - (8.0x10-39)	MASLD: - (.04)
ABCC2	rs17222723	10_99836239_T_A	0.0373403	ABCC2 (p.Val1188Glu)	-	ALT: - (3.3x10-75), Bilirubin: - (1.7x10-13), GGT: - (1.7x10-67)	
ASL	rs35135885	7_66010747_C_T	0.425519	Intergenic	Multiple	ALP: + (3.0x10-15)	MASLD: - (.04)
ATP8B1	rs12968116	18_57655270_C_T	0.0451278	ATP8B1 (p.Arg952Gln)	Blood	ALT: - (7.5x10-33), AST: - (1.1x10-10), Cholecystitis: (2.4x10-8), DirectBilirubin: - (4.0x10-11), GGT: - (1.2x10-49)	
BCS1L	rs1870125	2_218323178_C_T	0.472843	Intergenic	-	GGT: - (3.4x10-26)	MASLD: - (.007)
BCS1L	rs2292553	2_218282080_G_A	0.449481	Intergenic	Liver	ALP: - (6.5x10-19), Cholelithiasis: (1.0x10-8)	
CPS1	rs2193617	2_210708835_G_A	0.139177	Intergenic	Liver	ALT: + (1.0x10-14)	
DCDC2	rs2296538	6_24289365_C_T	0.101238	DCDC2, intronic_variant	-	ALP: - (7.0x10-146)	
GALK1	rs8081539	17_75796291_G_T	0.458866	Intergenic	Liver	DirectBilirubin: - (5.0x10-15)	
HFE	rs80215559	6_25917997_T_C	0.0129792	Intronic	-	ALP: + (2.4x10-48)	Cirrhosis: + (1.5x10-9)
HNF1B	rs1713847	17_37713312_C_A	0.138778	HNF1B,	Liver	Alb: + (2.4x10-14), ALT: -	

	8			intronic_variant		(2.4x10-30), AST_ALT_ratio: + (4.0x10-15), AST: - (2.0x10-9), Cholecystitis: (3.2x10-8), Cholelithiasis: + (1.0x10-11), GGT: - (5.5x10-19)	
JAG1	rs35761929	20_10641853_G_C	0.0529153	JAG1 (p.Pro871Arg)	-	Bilirubin: + (9.7x10-10), DirectBili: + (2.2x10-8) GGT: - (5.1x10-10)	
LIPA	rs2250781	10_89247713_C_A	0.370407	LIPA, intronic_variant	Liver	ALP: + (3.6x10-12), ALT: - (2.7x10-11)	
NOTCH2	rs10923931	1_119915381_A_T	0.192093	NOTCH2 (p.Gly2447=)	Liver	GGT: + (7.4x10-20)	
NPC2	rs8014204	14_74856091_G_A	0.334864	Intergenic	Liver	Bilirubin: - (8.5x10-10)	
PKD1	rs34197769	16_2094175_G_A	0.0662939	PKD1 (p.Ala3512Val)	Liver	ALP: - (8.8x10-26), GGT: - (1.3x10-8)	
SERPINA1	rs28929474	14_94378610_C_T	0.00399361	SERPINA1 (p.Glu366Lys)	Liver	Alb: + (1.2x10-283), ALT: + (2.3x10-102), GGT: + (4.1x10-41)	Cirrhosis: + (2.1x10-41)

Table 1. Top variant-trait associations in genes that also cause monogenic liver disease. Variants are annotated with: predicted protein functional effect (from Ensembl's Variant Effect Predictor), liver tissue eQTL data from GTEx, effect allele frequency (EAF) from gnomAD, and results from replication across six cohorts of patients with clinical liver disease.

		Unweighted monogenic gene PRS quartile				
Trait	**All**	**Q1**	**Q2**	**Q3**	**Q4**	**P-value**
N (% male)	291758 (40%)	88329 (39%)	81193 (40%)	69388 (40%)	52848 (40.0%)	-
ALP (IU/L)	76.2 (21.6)	76.4 (21.8)	76.3 (21.6)	76.0 (21.5)	75.8 (21.3)	3.23E-05
ALT (IU/L)	23.3 (10.0)	23.5 (10.1)	23.3 (9.9)	23.1 (9.9)	23.2 (9.9)	6.29E-09
AST (IU/L)	22.9 (7.0)	23.0 (7.1)	22.8 (7.0)	22.8 (7.0)	22.8 (7.0)	0.00047621
Total bilirubin (mg/dL)	0.518 (0.21)	0.504 (0.20)	0.513 (0.21)	0.523 (0.21)	0.542 (0.22)	1.11E-151
Conjugated bilirubin (mg/dL)	0.145 (0.07)	0.145 (0.07)	0.147 (0.07)	0.148 (0.07)	0.151 (0.07)	3.08E-18

Table 2. Monogenic gene polygenic risk score (PRS) is associated with liver enzymes and bilirubin levels. An unweighted PRS comprised of 35 variants in genes that cause monogenic liver disease was calculated in 291,758 individuals from the All of Us study. ANNOVA was used to compare the differences in liver enzymes between quartiles (Q1-Q4) of the PRS.